Longs opens new store in Hawaii, sees Walgreens challenge
HONOLULU Longs Drug Stores has opened a smaller-format pharmacy in Kaua’i, making it its 37th store in the state, the company announced last weekend.
“This store is going to be helpful to our pharmacy customers on the south side of the island,” said Longs spokeswoman Phyllis Proffer.
Proffer said California-based Longs, which has about 500 stores in several states, expects its number of stores to expand in the thousands, and will include a mix of both small pharmacy stores and full-size traditional stores, which will feature general merchandise and pharmacy operations.
The expansion in Hawaii comes as the nation’s largest drugstore chain, Walgreens, is pushing ahead with a goal to open as many as 40 stores in the state, with the first store slated to open in Honolulu in November.
CVS to offer flu vaccinations in more than 4,000 stores
WOONSOCKET, R.I. CVS/pharmacy plans to help Americans stay healthy by offering flu vaccinations in over 4,000 of its stores, the company said Wednesday.
The flu vaccinations, which will be offered to customers by Oct. 1, will vary in cost based on location. Vaccines for Medicare Part B beneficiaries who present their Medicare Card will be available at no charge, provided they have not assigned their Medicare benefits to a private Health Maintenance Organization. The offer to receive the flu shots will run through November.
“The annual flu shot clinics at CVS/pharmacy are part of our commitment to help communities stay healthy,” said Papatya Tankut, R.Ph., Vice President of Pharmacy Professional Services at CVS/pharmacy. “By offering convenient locations for flu vaccinations, we’re providing additional opportunities for people across the country to get vaccinated before the peak flu season begins.”
Last year, nearly 400,000 people received flu shots at CVS/pharmacy.
It is strongly recommended people ages 50 and older, and/or have chronic illnesses like diabetes and asthma, receive a yearly flu vaccination, according to the Centers for Disease Control.
Adams, Lipocine to develop new cough medicines
CHESTER, N.J. Lipocine and Adams Respiratory Therapeutics have entered in an agreement to develop new prescription adult cough products.
Under the terms of the agreement, Adams receives exclusive rights from Lipocine to develop and market multiple prescription adult cough products. Adams will be responsible for performing clinical development, regulatory submission, manufacture, and commercial operations. Lipocine will be responsible for completing the product development work.
Lipocine will have the opportunity to receive reimbursements and payments in exchange for completing development milestones. “Given the large and growing size of the respiratory market, and how patients can benefit from enhanced dosage forms and regimens, we are very pleased to partner with Adams, a company highly respected for its commercialization accomplishments,” said Dr. Mahesh Patel, president and chief executive officer of Lipocine.